HBY 946
Alternative Names: BAY-946; HBY-946; HOE-946; HOE-BAY-946; Hoe/Bay 946Latest Information Update: 09 Jul 2002
Price :
$50 *
At a glance
- Originator Aventis; Bayer
- Class Analgesics; Anti-inflammatories; Antiallergics; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 24 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 24 Nov 1997 Phase-II clinical trials for HIV infections treatment (Unknown route)
- 10 Jan 1997 Investigation in HIV infections treatment (Unknown route)